دانلود رایگان مقاله ارزیابی آسپرین برای پیشگیری در بیماری های ایسکمیک قلب

Aspirin was established more than a quarter century ago as an evidence-based therapy to reduce recurrent cardiovascular events in patients with coronary artery disease based on limited data by contemporary standards. Indeed it is unclear how regulatory agencies would define the optimal dose or duration of aspirin therapy if assessed in the current era. Subsequent clinical investigation has focused on the addition of antithrombotic agents on top of baseline aspirin therapy in the acute and chronic setting to reduce patient's risk of further ischemic events, at the cost of increased bleeding complications. The current armamentarium of potent and predictable antiplatelet and antithrombotic agents has ushered in a new era where clinicians and scientists are contemplating withdrawal of previously established agents to minimize bleeding risk while sustaining efficacy; indeed, subtraction may lead to the next advance in the treatment of acute and chronic ischemic vascular disease.

Conclusion

Aspirin was established more than a quarter century ago as one of the first evidence-based therapies to reduce recurrent cardiovascular events in patients with established coronary artery disease. Despite limitations of this early research and limited discussion of the associated bleeding complications, aspirin has been clinically applied as a panacea across the spectrum of cardiovascular diseases as a foundation or cornerstone therapy. The current era of evidence-based medical care encourages researchers and clinicians to integrate efficacy and safety into therapeutic decisions, but historically, aspirin's safety was not held to the same scrutiny as agents in the current era of rigorous governmental regulation and medical oversight. Investigation has previously been focused on the addition of further antithrombotic agents in addition to baseline aspirin in the acute and chronic setting to reduce patient's risk of further ischemic events, at the cost of increased bleeding complications. The current armamentarium of potent and predictable antiplatelet and antithrombotic agents has ushered in a new era where clinicians and scientists are contemplating withdrawal of agents to minimize bleeding risk while sustaining efficacy; indeed, subtraction may lead to the next advance in the treatment of acute and chronic ischemic vascular disease.